Use of anxiety and depression treatment in Hispanic multiple sclerosis patients of San Juan MS Center

2018 ◽  
Author(s):  
Astrid Diaz ◽  
Cristina Rubi ◽  
Ivonne Vicente
Keyword(s):  
Multiple Sclerosis ◽  
Anxiety And Depression ◽  
Depression Treatment ◽  
San Juan ◽  
Multiple Sclerosis Patients

Anxiety and depression in multiple sclerosis patients around diagnosis

2011 ◽  
Vol 307 (1-2) ◽  
pp. 86-91 ◽  
Author(s):  
Andrea Giordano ◽  
Franco Granella ◽  
Alessandra Lugaresi ◽  
Vittorio Martinelli ◽  
Maria Trojano ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Anxiety And Depression ◽  
Multiple Sclerosis Patients

scholarly journals Abundance of Stress, Anxiety and Depression in Multiple Sclerosis Patients

2013 ◽  
Vol 2 (2) ◽  
pp. 82-88 ◽  
Author(s):  
A. Dehghan ◽  
S. محمدخان کرمانشاهی ◽  
R. Memarian ◽  
◽  
◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Anxiety And Depression ◽  
Multiple Sclerosis Patients

Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trøndelag County, Norway

2009 ◽  
Vol 15 (12) ◽  
pp. 1495-1501 ◽  
Author(s):  
Ole-Petter Dahl ◽  
Eystein Stordal ◽  
Stian Lydersen ◽  
Rune Midgard
Keyword(s):  
Multiple Sclerosis ◽  
General Population ◽  
Depression Scale ◽  
Population Based ◽  
Anxiety And Depression ◽  
Multiple Sclerosis Population ◽  
Neuropsychiatric Manifestations ◽  
Duration Of Disease ◽  
Fatigue Severity ◽  
Multiple Sclerosis Patients

Anxiety and depression are widely distributed symptoms among multiple sclerosis patients and in the general population. We assessed the prevalence of anxiety and depression in the multiple sclerosis population in Nord-Trøndelag County, Norway compared with Norway’s general population. The Hospital Anxiety and Depression Scale questionnaire was completed by 172 MS patients and 56,000 controls. A cut-off of ≥8 was used to define significant symptoms of anxiety and depression. Fatigue was measured using Krupp’s Fatigue Severity Scale, with a mean cut-off of >4. Among men, 31.1% of the multiple sclerosis patients reported anxiety, while only 12.1% of the control population reported this symptom ( p = 0.002). For women, the prevalence of anxiety was 29.7% versus 17.4% ( p < 0.001). Depression was reported by 26.2% of the men with multiple sclerosis compared with 10.8% of the controls ( p < 0.001). The corresponding figures for women were 25.2% versus 10.4% ( p < 0.001). Anxiety and depression were not correlated with duration of disease or disability measured by the Expanded Disability Status Scale. Among women, fatigue was associated with anxiety ( p ≤ 0.010) and depression ( p = 0.007). No such association was found among men. Anxiety and depression occur more frequently in multiple sclerosis patients than in the general population. Fatigue was associated with these neuropsychiatric manifestations in only women.

Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients

2009 ◽  
Vol 15 (12) ◽  
pp. 1518-1524 ◽  
Author(s):  
Kimia Honarmand ◽  
Anthony Feinstein
Keyword(s):  
Multiple Sclerosis ◽  
Major Depression ◽  
Anxiety Disorders ◽  
Depression Scale ◽  
Area Under The Curve ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Dsm Iv ◽  
Roc Area ◽  
Multiple Sclerosis Patients

Detecting clinically significant symptoms of depression and anxiety in medically ill patients using self-report rating scales presents a challenge because of somatic confounders. The Hospital Anxiety and Depression Scale (HADS) was developed with this in mind, but has never been validated for a multiple sclerosis population. Our objective was to validate the HADS for multiple sclerosis patients. Multiple sclerosis patients were interviewed for the presence of major depression ( n = 180) and anxiety disorders ( n = 140) with the Structured Clinical Interview for DSM-IV disorders. A receiver operating characteristic (ROC) analysis was undertaken to assess which HADS cut-off scores give the best yield with respect to diagnoses of major depression and all anxiety disorders defined by the Structured Clinical Interview for DSM-IV. A threshold score of 8 or greater on the HADS depression subscale provides a sensitivity of 90% and specificity of 87.3% (ROC area under the curve 0.938). The same cut-off score gives a sensitivity of 88.5% and a specificity of 80.7% on the anxiety subscale (ROC area under the curve 0.913), but for generalized anxiety disorder only. The study confirms the usefulness of the HADS as a marker of major depression and generalized anxiety disorder, but not other anxiety disorders, in multiple sclerosis patients.

scholarly journals Relationship Between Anxiety and Depression with Disability Over Multiple Sclerosis Patients in Rafsanjan, Iran

2018 ◽  
Vol 5 (2) ◽  
Author(s):  
Amir Moghadam Ahmadi ◽  
Azam Mobini ◽  
Fariba Kabiri ◽  
Reza Bidaki ◽  
Bonnie Bozorg
Keyword(s):  
Multiple Sclerosis ◽  
Anxiety And Depression ◽  
Multiple Sclerosis Patients

scholarly journals Psychometric Properties of the HADS Measure of Anxiety and Depression Among Multiple Sclerosis Patients in Croatia

2021 ◽  
Vol 12 ◽  
Author(s):  
Ana Jerković ◽  
Ana Proroković ◽  
Meri Matijaca ◽  
Jelena Vuko ◽  
Ana Poljičanin ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Psychometric Properties ◽  
Factor Structure ◽  
Convergent Validity ◽  
Online Survey ◽  
Depression Scale ◽  
Psychological Status ◽  
Anxiety And Depression ◽  
Study Objective ◽  
Multiple Sclerosis Patients

Depression and anxiety are common complaints in patients with multiple sclerosis (MS). The study objective was to investigate the factor structure, internal consistency, and correlates of the Croatian version of the Hospital Anxiety and Depression Scale (HADS) in patients with MS. A total of 179 patients with MS and 999 controls were included in the online survey. All subjects completed the HADS and self-administered questionnaires capturing information of demographic, education level, disease-related variables, and the Multiple Sclerosis Impact Scale-29 (MSIS-29). Psychometric properties were examined by estimating the validity, reliability, and factor structure of the HADS in patients with MS. The two HADS subscales (anxiety and depression) had excellent internal consistencies (Cronbach’s α value 0.82–0.83), and factor analysis confirmed a two-factor structure. The convergent validity of the HADS subscales appeared to be good due to the significant correlations between HADS and MSIS-29. Receiver operating characteristic (ROC) analysis indicates that the HADS subscales have a significant diagnostic validity for group differentiation. Hierarchical regression analysis using MSIS-29 subscales as criterion variables showed consistent evidence for the incremental validity of the HADS. The HADS is a reliable and valid self-assessment scale in patients with MS and is suggested to be used in clinical monitoring of the psychiatric and psychological status of patients with MS.

scholarly journals SLEEP DISORDERS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS

2021 ◽  
Vol 74 (2) ◽  
pp. 257-262
Author(s):  
Tetiana A. Odintsova ◽  
Oksana O. Kopchak
Keyword(s):  
Multiple Sclerosis ◽  
Sleep Disorders ◽  
Negative Correlation ◽  
Significant Negative Correlation ◽  
Anxiety And Depression ◽  
Relapsing Remitting ◽  
Edss Score ◽  
Remitting Multiple Sclerosis ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

The aim: Our study aimed at evaluating the relationships between sleep disorders (SD), cognitive impairment (CI), anxiety and depression in patients with relapsing-remitting multiple sclerosis (RRMS). Materials and methods: One hundred and five patients with RRMS (80 females and 25 males) aged from 22 to 67 years (mean age: 41,8±10,7; EDSS:3,5±1,6; disease duration (DD): 10,3±8,5 years) were enrolled into the study. All participants completed questionnaires on sleep (the Pittsburgh Sleep Quality Index /PSQI), cognitive functions (The Montreal Cognitive Assessment /MoCA), anxiety (Hamilton Anxiety Rating Scale /HAM-A), depression (Beck Depression Inventory/ BDI). Results: According to PSQI score the patients were divided into two groups: with (n=42) and without SD (n=63). The patients with SD were older (45,36±1,66 vs 39,41±1,27, p=0.005), had higher EDSS score (3,98±0,26 vs 3,14±0,19, p=0,008), BDI (13,79±1,14 vs 8,96±0,86, p=0,0009) and HAM-A (24,52±1,42 vs 16,56±0,99, p<0,0001) scales compared with patients without SD. The frequency of anxiety (p=0,0034) and depression (p=0,038) was significantly higher in RRMS patients with compared to those without SD. No significant difference was found in gender, DD and MoCA score. In patients with SD significant negative correlation between MoCA and BDI score (r = -0,42, p<0,005) was found. In the group of patients without SD significant negative correlation between MoCA and EDSS (r = -0,27, p=0,03), MoCA and BDI (r = -0,26, p=0,043),) MoCA and HAM-A (r = -0,25, p=0,041) score was detected. Conclusions: Insomnia type SD in RRMS patients were associated with older age, higher EDSS score and presence of anxiety and depression.

scholarly journals Depression, anxiety and blood serotonin in patients with multiple sclerosis during Betaferon treatment

2008 ◽  
Vol 7 (5-2) ◽  
pp. 424-427
Author(s):  
T. N. Trushnikova ◽  
T. V. Bajdina
Keyword(s):  
Multiple Sclerosis ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Immunomodulating Therapy ◽  
Blood Serotonin ◽  
Immunoenzyme Analysis ◽  
Multiple Sclerosis Patients

Depression and anxiety were examined by Hospital Anxiety and Depression Scale and Spilberger Scale in 217 multiple sclerosis patients treated by Betaferon. The concentration of blood serotonin was determined by immunoenzyme analysis in 71 of them. The multiple sclerosis patients had progressive high levels of depression ((7,55 ± 3,61) points; р = 0,000) and anxiety ((7,55 ± 3,61) points; р = 0,000), and the decreased blood serotonin concentration ((210 ± 134,2) versus (269 ± 98,8) ng/ml; р = 0,036 in healthy people). The level of anxiety was related to the level of serotonin depression. Betaferon did not correct the affective disorders in multiple sclerosis patients, except the decreasing the degree of anxiety, and did not normalize the level of blood serotonin, that suggest the use of selective serotonin reuptake inhibitors during immunomodulating therapy.

Sign in / Sign up

Export Citation Format

Share Document